Skip to content
easybpt
Browse topics

Medical oncology

Prostate cancer

The 2026 Australian PSA testing guideline, MRI before biopsy, ISUP grade groups and risk groups, active surveillance versus radical treatment, androgen deprivation and its harms, and treatment intensification in hormone-sensitive and castration-resistant metastatic disease.

Tier 1Condition

Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made

3 questions9 flashcards

At a glance

  • The commonest cancer diagnosed in Australian men and the second commonest cause of male cancer death. Many cancers found by PSA are indolent; the task is finding the significant ones without overtreating the rest.
  • The 2026 PCFA guideline replaced the 2016 version: PSA every 2 years from 50 to 69 for men who choose testing, from 45 for higher risk, and GPs no longer do a DRE as part of testing.
  • MRI before biopsy, transperineal biopsy, and active surveillance for grade group 1 are now standard.

Loading the rest of the note…

Finished reading?

Test yourself on it:3 questions9 flashcards

Sources

Last updated
14 November 2026
What changed
  • 14 November 2026 Personal emails, About story and Australian-style copy

Send feedback

Type of feedback

The page you're on and your device type are attached automatically.